Advertisement

Ciprofloxacin Immediate-Release Tablets

[03 July 2014]

Products Affected - Description

Ciprofloxacin Immediate-Release Tablets, Carlsbad Technologies
250 mg, 100 count (NDC 61442-0222-01) - discontinued
250 mg, 1000 count (NDC 61442-0222-10) - discontinued
500 mg, 500 count (NDC 61442-0223-05) - discontinued
750 mg, 100 count (NDC 61442-0224-01) - discontinued
750 mg, 400 count (NDC 61442-0224-04) - discontinued
500 mg, 100 count (NDC 61442-0223-01) - discontinued
 
Ciprofloxacin Immediate-Release Tablets, Marlex
500 mg, 100 count (NDC 10135-0475-01)
 
Ciprofloxacin Immediate-Release Tablets, Ranbaxy
250 mg, 100 count (NDC 63304-0709-01)
500 mg, 100 count (NDC 63304-0710-01)
750 mg, 100 count (NDC 63304-0711-01)
750 mg, 50 count (NDC 63304-0711-50)

Reason for the Shortage

  • Ranbaxy has an FDA import ban on several of their products manufactured in India.
  • Carlsbad Technology discontinued ciprofloxacin tablets in 2014.
  • Marlex is unable to provide a reason for their shortage.
  • Major discontinued their ciprofloxacin immediate-release tablets in February, 2010.
  • Teva discontinued their ciprofloxacin immediate-release tablet, unit dose presentations in June, 2010.
  • Schering has discontinued all Cipro immediate-release tablet presentations.
  • UDL has discontinued all ciprofloxacin immediate-release 250 mg unit-dose tablets.

Available Products

Ciprofloxacin Immediate-Release Tablets, Dr. Reddy’s
250 mg, 100 count (NDC 55111-0126-01)
250 mg, 500 count (NDC 55111-0126-05)
500 mg, 100 count (NDC 55111-0127-01)
500 mg, 500 count (NDC 55111-0127-05)
750 mg, 50 count (NDC 55111-0128-50)
 
Ciprofloxacin Immediate-Release Tablets, Teva
250 mg, 100 count (NDC 00172-5311-60)
500 mg, 100 count (NDC 00172-5312-60)
500 mg, 500 count (NDC 00172-5312-70)
750 mg tablets, 100 count (NDC 00172-5313-60)

Ciprofloxacin Immediate-Release Tablets, UDL
500 mg, 100 count unit dose (NDC 51079-0182-20)

Ciprofloxacin Immediate-Release Tablets, Actavis (formerly Watson)
250 mg, 100 count (NDC 16252-0514-01)
500 mg, 100 count (NDC 16252-0515-01)
750 mg, 50 count (NDC 16252-0516-05)
 
Ciprofloxacin Immediate-Release Tablets, West-Ward
250 mg, 100 count (NDC 00143-9927-01)
500 mg, 100 count (NDC 00143-9928-01)
500 mg, 100 count (NDC 00143-2037-01)
750 mg, 50 count (NDC 00143-9929-50)

Estimated Resupply Dates

  • Marlex has ciprofloxacin immediate-release tablets on back order and the company cannot estimate a release date.
  • Ranbaxy has ciprofloxacin immediate-release tablets on back order and the company cannot estimate a release date.

Related Shortages

Updated

July 3, 2014; April 16, 2014; March 3, 2014; February 13, 2014; January 15, 2014; November 21, 2013; September 13, 2013; July 10, 2013; May 6, 2013; March 20, 2013; February 12, 2013; January 31, 2013; December 7, 2012; October 15, 2012; August 30, 2012; July 13, 2012; May 25, 2012; April 12, 2012; March 20, 2012; March 8, 2012; January 13, 2012; November 11, 2011; August 26, 2011; July 6, 2011; May 26, 2011; April 15, 2011; March 3, 2011; January 28, 2011; December 1, 2010; September 22, 2010; August 4, 2010; June 30, 2010; June 23, 2010; May 21, 2010; April 26, 2010; April 8, 2010; March 31, 2010; February 26, 2010; February 12, 2010; January 22, 2010; January 8, 2010; December 21, 2009; December 10, 2009; December 8, 2009; November 5, 2009; October 15, 2009, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement